Skip to main content
padlock icon - secure page this page is secure

SuperSAGE: A Modern Platform for Genome-Wide Quantitative Transcript Profiling

Buy Article:

$68.00 + tax (Refund Policy)

SuperSAGE is a variant of SAGE (Serial Analysis of Gene Expression) technology, which allows making transcript profiling by 26-bp tags extracted from cDNA employing the typeIII restriction enzyme EcoP15I. Its tag length is the longest among all the versions of SAGE, and is advantageous in tag-to-gene annotation, thereby allowing the technique to applicable to any eukaryotic life organisms. For model organisms with genome or cDNA sequences available, genes corresponding to 26-bp tags are uniquely defined by simple BLAST search. For non-model organisms without these sequence information, the 26-bp tag sequence is directly applicable to design PCR primer for amplifying cDNA of corresponding genes by 3'- or 5'-RACE. Furthermore, SuperSAGE allows various applications including “interaction transcriptome” and “SuperSAGE array”. Emerging “Next Generation Sequencing” technologies perfectly complement Super- SAGE, and their combination has generated a novel transcriptome platform, that is superior to all the different microarray variants in terms of throughput, data quality and cost of analysis.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Next Generation Sequencing; SuperSAGE; SuperSAGE array; Transcriptome; interaction transcriptome; microarray; non-model organism

Document Type: Research Article

Publication date: October 1, 2008

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more